Natco Pharma's Vizag facility gets two observations from USFDA

Natco Pharma has announced to the exchanges regarding completion of USFDA inspection at company’s Vizag Formulation facility.

In a regulatory filing, the company informed that the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Ramky SEZ, near Visakhapatnam (Vizag), India, which was conducted during the period January 30, 2023 to February 03, 2023.

At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure.

“The Company is confident of addressing all observations within the stipulated time”, Natco Pharma said.

At around 11:15 AM, Natco Pharma was trading at Rs531.95 per share higher by 0.71% on the BSE.